Kainova Therapeutics

About Kainova Therapeutics

Kainova Therapeutics, formerly Domain Therapeutics, is a clinical-stage biopharmaceutical company focused on developing breakthrough GPCR-modulating therapies in immuno-oncology and inflammation. Driven by a commitment to bold science and collaboration, the company aims to deliver better outcomes for patients with underserved medical needs through first-in-class and best-in-class programs that redefine standards of care.

Products & Services

DT-9081 (EP4 Receptor Antagonist):A Phase II-ready oral small molecule designed to reverse PGE2-mediated immunosuppression in solid tumors, aiming to restore immune competence and drive tumor regression. Currently in Phase 1 trials.

DT-7012 (Anti-CCR8 Depleting Antibody):A Phase I/II anti-CCR8 monoclonal antibody targeting immunosuppressive regulatory T cells in solid tumors to promote tumor regression. First patients dosed in Phase I/II trials.

DT-9046 (PAR2 Biased Antagonist):A pre-IND, first-in-class oral small molecule for inflammatory diseases like atopic dermatitis and IBD, designed to modulate Th2 immune responses with a unique mechanism of action.

Undisclosed GPCR Targets:A portfolio of novel GPCR targets in discovery phase for immuno-oncology and inflammation, leveraging proprietary platforms to address unmet needs with potential first-in-class therapies.

Specialties

GPCR-modulating therapies Immuno-oncology Inflammation Drug discovery and development Precision medicine Translational research

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series B T: - FT: Series B	A: 32000000 MR: - FA: $32 million CAD FAN: 32000000	D: 2026-02-10 FD: 2026-02-10	10 investors

Series B Latest

2026-02-10

$32.0M

10 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

S

Sean A. MacDonald

Chief Executive Officer

LinkedIn (Pro only)

J

Jean-Marie Cuillerot

Chief Medical Officer

LinkedIn (Pro only)

S

Stephan Schann

Chief Scientific Officer

LinkedIn (Pro only)

S

Stanislas Malmezat

Chief Financial Officer

N

Nathalie Lenne

Vice-President Strategic Portfolio Management

M

Marjorie Sidhoum

Vice-President Business Development & Corporate Communication

View 15 more team members with Pro

Unlock Full Team Directory

Recent News